Neuromyelitis optica spectrum disorder Registry (Japan Neuroimmune Disease Registry)

Neuromyelitis optica spectrum disorder Registry (Japan Neuroimmune Disease Registry) - JANIMA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051988

Enrollment

1000

Registered

2023-12-01

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroimmune Disease (Neuromyelitis Optica Spectrum Disorders, MOG antibody-associated disease)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: As follows: Neuromyelitis Optica Spectrum Disorder (NMOSD) 1) Patients who meet the Wingerchuk 2015 criteria (International Panel criteria) 2) Patients who have given written consent to participate in the study Anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) 1) Patients who meet the International Panel 2023 criteria 2) Patients who have given written consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients deemed inappropriate for inclusion by the investigator.

Design outcomes

Primary

Measure	Time frame
The course of clinical endpoints mainly used for each neuroimmune disease.	—

Secondary

Measure	Time frame
1. Severity (EDSS, Functional Score, mRS) 2. Presence or absence of recurrence and timing 3. Cerebrospinal fluid findings, imaging (MRI) findings 4. Treatment history 5. Adverse events 6. EQ-5D-5L survey	—

Countries

Japan

Contacts

Public ContactJuichi Fujimori

School of Medicine, Tohoku Medical and Pharmaceutical University Division of Neurology, Professor

info@kizuna-cro.org0222908850

Outcome results